Edgewise Therapeutics Inc. Common Stock vs Guardant Health Inc. Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.13 (market cap $3.94B), while Guardant Health Inc. Common Stock trades at $162.64 (market cap $21.74B). The key difference: Guardant Health Inc. Common Stock is far larger — about 5.5× Edgewise Therapeutics Inc. Common Stock's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, Edgewise Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Guardant Health Inc. Common Stock for 3 Days on average.
| EWTX | GH | |
|---|---|---|
Market Cap | $3.94B | $21.74B |
Volume | 810,104 | 1,297,295 |
Sector | Health | Health |
52-Week High | $48.35 | $187.22 |
52-Week Low | $14.89 | $64.19 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $3.48B | $22.38B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →